atai Life Sciences and Massachusetts General Hospital announce the initiation of a clinical study evaluating neuroplasticity biomarkers in ketamine-treated patients with treatment-resistant depression

NEW YORK and BERLIN, Nov. 18, 2022N.V.(MGH) announced. The study will use an imaging technique to identify neuroplasticity biomarkers in patients with treatment-resistant depression who are being treated with intravenous …

Read more

Gray matter volume may be indicative of treatment decisions for developing mental disorders

The structure of the brain of patients with recent-onset psychosis and depression can offer important biological insights into these diseases and their possible development, as well as suggest the best …

Read more